Ubs Group Ag Genmab A/S Transaction History

Ubs Group Ag

$452 Billion
Q3 2024

A detailed history of Ubs Group Ag transactions in Genmab A/S stock. As of the latest transaction made, Ubs Group Ag holds 60,448 shares of GMAB stock, worth $1.24 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

60,448

Previous 62,408 3.14%

Holding current value

$1.24 Million

Previous $1.57 Million 6.06%

% of portfolio

0.0%

Previous 0.0%

21 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$23.84 - $28.48 $46,726 - $55,820	-1,960 Reduced 3.14%	60,448 $1.47 Million
Q2 2024 Aug 13, 2024	BUY	$25.13 - $30.27 $319,251 - $384,550	12,704 Added 25.56%	62,408 $1.57 Million
Q1 2024 May 13, 2024	BUY	$26.43 - $32.77 $61,925 - $76,780	2,343 Added 4.95%	49,704 $1.49 Million
Q4 2023 Feb 09, 2024	SELL	$27.94 - $35.44 $36,405 - $46,178	-1,303 Reduced 2.68%	47,361 $1.51 Million
Q3 2023 Nov 09, 2023	SELL	$35.27 - $42.24 $844,998 - $1.01 Million	-23,958 Reduced 32.99%	48,664 $1.72 Million
Q2 2023 Aug 11, 2023	BUY	$37.4 - $42.94 $277,433 - $318,528	7,418 Added 11.38%	72,622 $2.76 Million
Q1 2023 May 12, 2023	BUY	$34.88 - $43.22 $287,725 - $356,521	8,249 Added 14.48%	65,204 $2.46 Million
Q4 2022 Feb 08, 2023	BUY	$33.8 - $47.06 $653,996 - $910,563	19,349 Added 51.45%	56,955 $2.41 Million
Q3 2022 Nov 10, 2022	SELL	$31.52 - $373.61 $167,780 - $1.99 Million	-5,323 Reduced 12.4%	37,606 $1.21 Million
Q2 2022 Aug 10, 2022	SELL	$26.83 - $38.57 $681,508 - $979,716	-25,401 Reduced 37.17%	42,929 $1.4 Million
Q1 2022 May 16, 2022	BUY	$30.95 - $39.68 $94,861 - $121,619	3,065 Added 4.7%	68,330 $2.47 Million
Q4 2021 Feb 14, 2022	SELL	$35.87 - $47.12 $138,207 - $181,553	-3,853 Reduced 5.57%	65,265 $2.58 Million
Q3 2021 Nov 15, 2021	BUY	$41.55 - $48.72 $854,932 - $1 Million	20,576 Added 42.39%	69,118 $3.02 Million
Q2 2021 Aug 13, 2021	BUY	$32.88 - $44.57 $63,096 - $85,529	1,919 Added 4.12%	48,542 $1.98 Million
Q1 2021 May 12, 2021	BUY	$30.92 - $44.4 $705,996 - $1.01 Million	22,833 Added 95.98%	46,623 $1.53 Million
Q4 2020 Feb 11, 2021	BUY	$33.66 - $40.76 $124,407 - $150,648	3,696 Added 18.39%	23,790 $967,000
Q3 2020 Nov 12, 2020	BUY	$33.07 - $38.68 $219,320 - $256,525	6,632 Added 49.26%	20,094 $736,000
Q2 2020 Jul 31, 2020	BUY	$20.05 - $33.89 $155,146 - $262,240	7,738 Added 135.19%	13,462 $456,000
Q1 2020 May 01, 2020	BUY	$17.15 - $25.22 $9,158 - $13,467	534 Added 10.29%	5,724 $121,000
Q4 2019 Feb 14, 2020	BUY	$18.88 - $24.14 $10,138 - $12,963	537 Added 11.54%	5,190 $116,000
Q3 2019 Nov 14, 2019	BUY	$18.0 - $21.38 $83,754 - $99,481	4,653 New	4,653 $94,000

Others Institutions Holding GMAB

# of Institutions

236

Shares Held

52.5M

Call Options Held

10.2K

Put Options Held

25.5K

View Full List

About GENMAB A/S

Ticker GMAB
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 658,292,992
Market Cap $13.6B
Description
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphoc...

More about GMAB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account